WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance
from the FDA to market a new formulation of Zoladex (goserelin
acetate implant) for the palliative treatment of advanced prostate
The new formulation, a 10.8-mg goserelin acetate implant given
every 3 months, offers greater convenience to patients choosing
treatment with a luteinizing-hormone-releasing hormone (LHRH)
analog, the company said.
The original 1-month 3.6-mg formulation of Zoladex implants has
been available in the United States since 1989 for the treatment
of advanced prostate cancer. The drug has been marketed since
1993 for the treatment of endometriosis, and it was recently cleared
by the FDA for the treatment of advanced breast cancer in premenopausal
and perimeno-pausal women.